Biocon Limited (NSE:BIOCON)
India · Delayed Price · Currency is INR | Market Cap | 568.60B +19.6% |
| Revenue (ttm) | 173.21B +9.8% |
| Net Income | 4.95B +28.6% |
| EPS | 3.37 +4.9% |
| Shares Out | 1.63B |
| PE Ratio | 103.72 |
| Forward PE | 70.98 |
| Dividend | 0.50 (0.14%) |
| Ex-Dividend Date | Jul 3, 2026 |
| Volume | 1,974,457 |
| Open | 352.60 |
| Previous Close | 352.00 |
| Day's Range | 348.00 - 353.00 |
| 52-Week Range | 337.70 - 447.15 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 440.68 (+26.2%) |
| Est. Earnings | Nov 5, 2026 |
About Biocon
Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and... [Read more]
Financial Performance
In fiscal year 2026, Biocon's revenue was 169.27 billion, an increase of 10.91% compared to the previous year's 152.62 billion. Earnings were 3.86 billion, a decrease of -61.95%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for BIOCON stock is "Buy." The 12-month stock price target is ₹440.68, which is an increase of 26.20% from the latest price.
News
Biocon settles Roche's US patent lawsuit over proposed breast-cancer drug copy
Roche's Genentech has settled a US lawsuit against Indian biopharmaceutical company Biocon over its proposed biosimilar of Genentech's blockbuster breast-cancer drug Perjeta, Biocon said Wednesday.
Biocon's Pertuzumab Biosimilar Receives Positive EMA CHMP Recommendation
(RTTNews) - Wholly owned subsidiary of Biocon Limited (BIOCON.NS), Biocon Biologics Limited said that the EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion reco...
Biocon Signs Brazil Pertuzumab Deal With Bahiafarma And Bionovis
(RTTNews) - Biocon Ltd. (532523, BIOCON), a biopharmaceutical company, announced the signing of a partnership agreement with Bahiafarma and Bionovis in Brazil for Pertuzumab, a monoclonal antibody use...
Don’t taunt me as billionaire: Kiran Mazumdar Shaw
Biocon chief Kiran Mazumdar-Shaw hits back at Anekal MLA Shivanna over poor roads, says “Don’t taunt me as a billionaire,” raising citizens’ concerns.
Biocon Transcript: Q1 26/27
Q1 FY 2027 saw 10% revenue growth, led by strong biosimilars and generics performance, while services declined. Profitability improved with margin expansion and lower interest costs. Outlook remains positive, with accelerated growth expected in the second half.
Biocon Quarterly report: Q1 2027
Biocon has published its Q1 2027 quarterly earnings report on August 6, 2026.
Biocon Slides: Q1 2027
Biocon has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 6, 2026.
Biocon Q1 net profit surges fourfold to Rs 141 cr
Biocon Q1 FY27 net profit jumps to Rs 141 crore on strong biosimilars and generics growth; revenue rises 9% to Rs 4,391 crore despite Syngene dip.
India's Biocon posts more than fourfold jump in quarterly profit on strong biosimilars growth
Indian biopharmaceutical company Biocon reported a more than fourfold jump in first-quarter net profit on Wednesday on strong revenue growth from its biosimilars segment.
Roche sues Biocon over proposed breast-cancer drug copy
Roche's Genentech has sued Indian biopharmaceutical company Biocon in New Jersey federal court, alleging its proposed biosimilar of Genentech's blockbuster breast-cancer drug Perjeta would infringe Ge...
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows
Mylan Inc, part of a global healthcare company Viatris , plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd , worth up to 34.81 billion Indian rupees ($363 million), according to a t...
Pharma sector stocks today, July 1: Panacea Biotec surges 4.30%, Biocon jumps 1.78%, Wockhardt up 1.66%
The Indian pharmaceutical sector displayed mixed performance in early trading on July 1, 2026. The S&P BSE Healthcare index stood at 49,349.56, up 0.09%. Broader market indices also opened positively,...
Top stocks to buy: Stock market recommendations for today - check list
Stock market recommendations: JSW Energy, Biocon, BHEL, and City Union Bank - these are the top stocks to buy recommended by Somil Mehta, Head of Retail Research at Mirae Asset Sharekhan for June 30, ...
Kiran Mazumdar-Shaw calls Bengaluru 'garbage city', sparks debate
Biocon founder Kiran Mazumdar-Shaw has voiced strong criticism regarding Bengaluru's urban development, lamenting the loss of its 'garden city' identity. She shared a stark visual comparison of curren...
Biocon's partner Duopharma Biotech secures over MYR 225 million in insulin tenders in Malaysia
Biocon Limited has announced that its partner, Duopharma Biotech Berhad, has secured multiple insulin contracts from Malaysia's Ministry of Health valued at over MYR 225 million this year. These contr...
Biocon announces 10% final dividend for FY 2025-26 with TDS details
Biocon has announced a final dividend of 10%, equivalent to ₹0.50 per equity share, for the financial year ending March 31, 2026. The dividend proposal, decided at the Board meeting…
Accessing capital still difficult for women entrepreneurs today: Biocon founder Kiran Mazumdar-Shaw
Biocon founder Kiran Mazumdar Shaw says women entrepreneurs still struggle to access capital; Bajaj Auto Foundation commits Rs 400 crore for women engineering scholarships.
Biocon invests Rs 5.47 crore in Ampin C&I Power Twelve for solar power stake
Biocon Limited has announced an investment of ₹5,47,60,000 in Ampin C&I Power Twelve Private Limited (AMPIN), acquiring a significant equity stake in the renewable energy company. This strategic move ...
Biocon issues reminder to shareholders for unclaimed dividends before August 2026 deadline
Biocon Limited has issued a reminder to its shareholders to claim unclaimed dividends from the financial year 2018-19 before the deadline of August 20, 2026. The company has highlighted that…
Pharma Stocks Today, May 13: Wockhardt rises 1.97%, Orchid Pharma falls 1.79%, Biocon gains 1.38%
Indian pharmaceutical stocks showed a mixed trend on May 13 2026 during the early morning trading session. The BSE Healthcare index remained nearly flat, rising marginally by 0.04% to 46,087.93.…
Top gainers today: oil India at ₹490.95 up 7.66%, ONGC at ₹294.50 up 4.80%, biocon at ₹402.45 up 3.07%
In a session marked by overall declines in the Indian stock market, with the Sensex down 1.92% at 74,559.24 and the Nifty 50 dropping 1.83% to 23,379.55, several stocks managed…
Pharma sector stocks fall today, May 12: Orchid Pharma falls 3.74%, J.B. Chemicals down 2.67%, Biocon rises 0.79%
Indian pharmaceutical stocks opened lower on May 12 2026. The BSE Healthcare index declined 0.74% to 46,474.08 in the early morning trade. The broader market also remained weak with the…
Pharma Stocks Today, May 11: Torrent Pharma up 3.77%, Lupin falls 4.50%, Biocon rises 3.36%
Pharmaceutical stocks displayed a mixed trend on May 11 2026 during the afternoon trading session. The BSE Healthcare index managed to rise 0.93% to 46,965.52, showing relative strength even as…
Biocon Pharma receives Health Canada approval for micafungin injection
Biocon Pharma Limited, a subsidiary of Biocon Limited, has secured approval from Health Canada for its micafungin for injection, USP, available in 50 mg and 100 mg dosages. This approval…
Biocon Earnings Call Transcript: Q4 2026
Q4 FY 2026 saw strong revenue and margin growth, driven by biosimilars and successful business integration. Focus shifts to execution, margin expansion, and de-leveraging, with no major CapEx planned and new product launches expected to drive growth in FY 2027.